The four previous reports of HER2 expression in DTCs in patients with operable breast cancer utilized immunofluorescence and immunocytochemical staining with a HER2-specific antibody and RT-PCR for HER2 mRNA evaluation 31,32–34. This evidence concerns the gene ERBB2 and breast carcinoma.